Comparing Wellgistics Health (NASDAQ:WGRX) and Jupiter Neurosciences (NASDAQ:JUNS)

Jupiter Neurosciences (NASDAQ:JUNS) and Wellgistics Health (NASDAQ:WGRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares Jupiter Neurosciences and Wellgistics Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%
Wellgistics Health	-545.69%	N/A	-145.69%

Volatility & Risk

Jupiter Neurosciences has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500. Comparatively, Wellgistics Health has a beta of -1.47, meaning that its share price is 247% less volatile than the S&P 500.

Earnings and Valuation

This table compares Jupiter Neurosciences and Wellgistics Health”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20,000.00	322.89	-$8.65 million	($0.27)	-0.66
Wellgistics Health	$23.34 million	0.32	-$101.28 million	($44.50)	-0.07

Jupiter Neurosciences has higher earnings, but lower revenue than Wellgistics Health. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than Wellgistics Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Jupiter Neurosciences and Wellgistics Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1	0	0	0	1.00
Wellgistics Health	1	0	0	0	1.00

Summary

Jupiter Neurosciences beats Wellgistics Health on 5 of the 9 factors compared between the two stocks.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

About Wellgistics Health

Founded in 2022, Wellgistics Health is a holding company for various existing and planned strategic businesses centered around pharmaceuticals and healthcare services. As a micro health ecosystem, our portfolio of companies consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services. We are focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. In January 2023 and May 2023, Wellgistics Health entered into separate definitive agreements with the owners of Wood Sage and Wellgistics LLC, respectively, whereby Wellgistics Health would acquire all of the respective outstanding membership interests of Wood Sage and Wellgistics LLC. In June 2024, Wellgistics Health and Wood Sage entered into an amended and revised definitive agreement and closed on the Wood Sage Acquisition, thereby making Wood Sage a wholly owned subsidiary of Wellgistics Health. In connection with the Wood Sage Acquisition, Wellgistics Health acquired Wood Sage’s two operating subsidiaries, APS—a pharmaceutical technology hub—and CSP—a retail community specialty pharmacy. On August 30, 2024, Wellgistics Health closed on the Wellgistics Acquisition, thereby making Wellgistics LLC—a company focused on wholesale operations including the distribution and fulfillment of certain pharmaceutical medications to a network of independent pharmacies meant to improve market access to and patient outcomes regarding the medications—a wholly owned subsidiary of Wellgistics Health. As such, Wellgistics Health currently exists as a holding company with Wood Sage as a directly held intermediate holding company subsidiary, APS and CSP as indirect operating subsidiaries, and Wellgistics LLC as a direct operating subsidiary. On October 4, 2024, the Company changed its corporate name to “Wellgistics Health, Inc.” by filing a duly authorized Certificate of Amendment to its Certificate of Incorporation. Despite that Wellgistics Health only recently closed the Wood Sage Acquisition and the Wellgistics Acquisition during 2024, the three companies have shared common office space, comarketed solutions to the marketplace, and leveraged financial and back-office support prior to June 2024. As such, Wellgistics Health’s management believes that its close business relationships have and will continue to limit the need for post-closing integration. The mailing address of our principal executive office is 3000 Bayport Drive, Suite 950 Tampa, FL.